Researchers and regulators express concerns about the safety of Celebrex and Bextra, similar to Vioxx.
Dr. Eric Topol criticizes the FDA for not investigating Vioxx's heart risks earlier.
FDA officials face resistance to findings on drug safety.
Merck withdraws Vioxx due to outweighing risks.
FDA's hands-off approach to post-market monitoring raises concerns.
Calls for more thorough, ongoing drug testing arise.
Advertising's impact on drug prescriptions is questioned.
Pfizer warns about Bextra's heart risks in surgery patients.
The withdrawal of Vioxx prompts scrutiny of drug safety monitoring.
